iCAD, Inc. (NASDAQ:ICAD) Short Interest Up 9.2% in March

iCAD, Inc. (NASDAQ:ICAD) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 451,300 shares, a growth of 9.2% from the March 15th total of 413,100 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average trading volume of 210,300 shares, the short-interest ratio is currently 2.1 days.

iCAD Trading Down 1.3 %

Shares of NASDAQ:ICAD traded down $0.02 during trading on Wednesday, reaching $1.58. The company had a trading volume of 41,102 shares, compared to its average volume of 196,744. The company has a fifty day moving average of $1.62 and a two-hundred day moving average of $1.59. The stock has a market capitalization of $41.93 million, a P/E ratio of -7.36 and a beta of 1.34. iCAD has a 12 month low of $1.05 and a 12 month high of $3.97.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings results on Tuesday, March 12th. The technology company reported ($0.02) EPS for the quarter. The company had revenue of $4.74 million during the quarter. iCAD had a negative return on equity of 21.63% and a negative net margin of 27.08%.

Hedge Funds Weigh In On iCAD

A number of institutional investors have recently made changes to their positions in the stock. Salem Investment Counselors Inc. bought a new position in shares of iCAD during the 1st quarter valued at $119,000. Vanguard Group Inc. grew its holdings in shares of iCAD by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 1,087,355 shares of the technology company’s stock valued at $1,925,000 after purchasing an additional 31,510 shares during the last quarter. Corient Private Wealth LLC bought a new position in shares of iCAD during the 4th quarter valued at $73,000. First Eagle Investment Management LLC grew its holdings in shares of iCAD by 2.8% during the 4th quarter. First Eagle Investment Management LLC now owns 679,525 shares of the technology company’s stock valued at $1,203,000 after purchasing an additional 18,689 shares during the last quarter. Finally, Tritonpoint Wealth LLC bought a new position in shares of iCAD during the 4th quarter valued at $83,000. Institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography.